Tvardi Therapeutics, Inc.
TVRD
$3.75
-$0.16-4.09%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -23.77% | 146.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -33.05% | 103.70% | |||
| Operating Income | 33.05% | -103.70% | |||
| Income Before Tax | -232.64% | 143.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -232.64% | 143.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -232.64% | 143.50% | |||
| EBIT | 33.05% | -103.70% | |||
| EBITDA | 33.14% | -104.30% | |||
| EPS Basic | -216.64% | 133.77% | |||
| Normalized Basic EPS | -216.66% | 133.76% | |||
| EPS Diluted | 41.25% | 32.89% | |||
| Normalized Diluted EPS | -219.61% | 132.93% | |||
| Average Basic Shares Outstanding | 13.71% | 28.83% | |||
| Average Diluted Shares Outstanding | 10.90% | 32.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||